LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
4 7 5 6 6 2 4 4 — —
P/E ratio
0.00 39.92 157.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1.74 1.79 1.60 1.68 2.82 1.26 2.13 2.54 4.09 2.76
P/S ratio
2.42 2.00 2.36 2.89 4.28 3.44 3.36 4.01 3.80 2.30
Altman Z″-Score (non-manufacturers)
0.72 2.26 1.44 1.23 0.11 0.19 0.49 0.63 4.19 4.19
P/FCF ratio
18.94 18.93 72.24 73.68 60.06 0.00 0.00 46.43 65.95 48.29
P/Operating CF
40.73 31.91 50.52 157.79 132.22 86.99 1,272.49 212.35 217.84 54.27
Beneish M-Score
(3.30) (2.82) (2.35) (2.95) (2.93) (3.36) (2.77) (3.12) (2.32) —
P/B ratio
2.80 1.90 2.13 2.44 3.42 2.90 2.64 2.95 2.12 1.30
Price to Tangible BV
18.94 7.54 11.67 41.99 0.00 0.00 0.00 0.00 7.77 3.86
EV/Sales
2.23 1.93 2.37 2.91 4.31 3.87 3.62 4.12 3.86 2.38
EV/EBITDA
10.98 11.97 239.67 22.59 53.16 0.00 0.00 0.00 18.48 14.09
EV/Operating CF
12.18 13.20 36.51 42.58 43.48 (45.58) (43.05) 37.82 42.73 25.48
EV/FCF
17.48 18.21 72.48 74.33 60.48 (30.73) (32.92) 47.70 66.85 50.10
Quick Ratio
1.05 2.34 2.37 2.35 0.56 1.41 0.62 0.61 0.93 0.72
Current Ratio
1.36 2.87 2.95 2.98 0.97 2.29 1.07 1.07 2.14 2.32
Net Debt/EBITDA
(0.92) (0.48) 0.77 0.20 0.38 (2.49) (6.29) (0.74) 0.25 0.51
Debt/Assets
14.45% 25.04% 24.15% 23.60% 10.88% 27.32% 14.00% 6.60% 5.83% 5.24%
Debt/Equity
0.31 0.48 0.46 0.45 0.19 0.59 0.24 0.11 0.08 0.07
Asset Turnover
0.54 0.51 0.49 0.45 0.45 0.39 0.44 0.44 0.42 0.39
Operating CF/Net income
(1.05) 2.89 4.27 (0.81) (0.75) 0.23 0.58 (0.64) (3.64) (1.44)
Capex/Depreciation
(0.89) (0.65) (0.42) (0.13) (0.30) (0.31) (0.22) (0.28) (0.25) (0.29)
Interest Coverage
4.05 2.05 (1.16) (1.59) (0.02) (6.71) (11.37) (25.25) 12.37 3.15
ROE
(19.24%) 4.87% 1.41% (6.89%) (11.30%) (27.98%) (10.92%) (11.41%) (1.42%) (3.57%)
ROA
(9.49%) 2.56% 0.74% (3.84%) (5.90%) (14.50%) (6.35%) (7.50%) (1.04%) (2.56%)
ROIC
13.24% 6.59% (3.33%) (3.89%) (0.04%) (11.32%) (6.46%) (9.54%) 3.23% 1.17%
Return on Tangible Assets
(45.22%) 6.98% 2.17% (11.72%) (102.68%) (61.98%) (72.23%) (83.09%) (3.82%) (9.42%)
Average Days of Receivables
56.80 56.25 68.05 65.41 65.34 72.03 86.78 84.46 101.73 80.67
Research and Development Expense of Revenue
13.38% 14.56% 16.80% 15.25% 17.71% 16.37% 13.54% 13.18% 10.82% 8.51%
Selling, General and Administrative Expense of Revenue
39.54% 40.60% 43.58% 45.92% 45.58% 47.80% 48.74% 42.00% 37.55% 36.81%
Intangible Assets out of Total Assets
0.39 0.39 0.43 0.50 0.59 0.57 0.63 0.68 0.53 0.48
Share Based Compensation of Revenue
2.61% 2.71% 3.15% 4.39% 3.92% 3.76% 3.00% 2.43% 1.88% 2.03%
Graham Net Nets
(0.09) (0.02) (0.06) (0.07) (0.05) (0.18) (0.13) (0.12) 0.05 0.08
Graham Number
0.00 25.21 13.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(7.23%) 2.50% 0.63% (2.92%) (3.04%) (10.69%) (4.26%) (4.27%) (0.65%) (2.85%)
Free Cash Flow Yield
5.28% 5.28% 1.38% 1.36% 1.67% (3.66%) (3.27%) 2.15% 1.52% 2.07%
Revenue per Share
25.45 23.11 21.39 19.11 20.45 19.23 22.42 22.83 21.02 19.75
Operating CF per Share
4.66 3.37 1.39 1.31 2.03 (1.63) (1.89) 2.48 1.90 1.85
Capex per Share
(1.35) (0.87) (0.63) (0.50) (0.50) (0.72) (0.58) (0.49) (0.58) (0.76)
Free Cash Flow per Share
3.31 2.51 0.76 0.81 1.52 (2.36) (2.46) 1.99 1.31 1.08
Cash per Share
11.65 13.34 10.71 9.64 4.11 5.20 1.26 0.97 1.94 0.81
Shareholders Equity per Share
22.00 24.34 23.69 22.58 25.57 22.83 28.62 31.01 37.70 34.93
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
22.00 24.34 23.69 22.58 25.57 22.83 28.62 31.01 37.70 34.93
Free Cash Flow
180.57 136.02 41.09 43.40 77.07 (114.45) (119.12) 96.71 63.17 52.93
Working Capital
293.54 735.06 653.18 588.74 (17.79) 398.99 36.89 36.55 463.84 462.80
Capital Expenditures
(73.77) (47.02) (33.83) (26.52) (25.48) (35.02) (27.98) (23.78) (28.17) (37.22)
Net Current Asset Value
(304.45) (58.94) (163.78) (201.01) (227.12) (582.65) (478.64) (512.67) 181.28 176.97
EV/EBIT
15.53 18.72 0.00 0.00 0.00 0.00 0.00 0.00 40.45 68.69
Capex to Sales
0.05 0.04 0.03 0.03 0.02 0.04 0.03 0.02 0.03 0.04
Price to Operating Income
16.83 19.46 0.00 0.00 0.00 0.00 0.00 0.00 39.90 66.20
Other line items
Depreciation/Fixed assets
0.34 0.43 0.52 1.42 0.56 0.69 0.70 0.44 0.60 0.64
Cash ROIC
8.16% 5.09% 1.68% 1.92% 4.42% (5.67%) (6.68%) 5.63% 3.07% 2.83%
Accounts Receivable Turnover
6.79 6.14 5.79 5.55 5.60 4.23 4.22 4.11 4.09 3.97
Accounts Payable Turnover
5.37 5.31 5.13 4.42 4.65 4.26 4.43 4.57 4.57 4.47
Inventory Turnover
2.87 2.71 2.87 2.67 2.98 2.43 2.27 2.50 2.60 2.35
Average Days of Payables
79.12 63.63 74.19 86.22 75.36 79.21 87.00 75.29 87.00 64.77
Days of Inventory on Hand
134.13 134.67 135.72 150.12 117.29 123.95 166.27 150.65 146.30 119.77
Average Receivables
204.57 204.12 199.09 184.23 184.86 221.06 256.95 269.14 247.70 242.80
Average Payables
83.44 75.29 77.58 71.16 70.83 79.78 81.31 81.33 78.92 90.76
Average Inventory
156.13 147.73 138.63 117.61 110.56 139.72 158.84 149.00 138.74 172.73
Average Assets
2,556.22 2,467.98 2,362.17 2,247.86 2,300.46 2,405.88 2,480.75 2,526.80 2,423.26 2,450.69
Average Common Equity
1,260.12 1,298.94 1,242.63 1,251.13 1,201.96 1,246.49 1,443.73 1,659.53 1,761.11 1,759.19

Fold the line items

Columns are period end dates